Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: results from the phase II FENopta study

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2023
This article has no abstract
Epistemonikos ID: a2b166b5415a8dd7678920802e3db846134cc362
First added on: Apr 30, 2026